<DOC>
	<DOCNO>NCT02351011</DOCNO>
	<brief_summary>Osteoarthritis ( OA ) one common form arthritis . It lasting condition material cushion joint , call cartilage , breaks . This cause bone rub , cause inflammation , stiffness , pain loss joint movement . Currently , effective treatment available patient suffer OA . Mesenchymal stem cell ( MSCs ) cell ability self-regenerate , mean ability make copy turn kind cell ( e.g . cartilage cell ) . Stem cell science show much promise future treatment osteoarthritis , much research still early stage . In study , researcher want determine safety MSCs patient tolerate without cause side effect . This do start low dose MSCs move next high dose level provide safety concern . Researchers also look function knee time , may give insight usefulness MSCs treatment option .</brief_summary>
	<brief_title>Human Autologous MSCs Treatment Mid Late Stage Knee OA</brief_title>
	<detailed_description>The trial non-randomized , open-label , dose escalation phase I/II clinical trial . A total 12 participant enrol - patient treat cohort 3 determine safety preliminary efficacy autologous , ex-vivo expand bone-marrow derive MSC inject knee joint patient moderate advance knee osteoarthritis . A minimum three evaluable patient enter dose level maximum tolerate dose ( MTD ) reach . Toxicity evaluate graded accord Common Terminology Criteria ( CTC ) Adverse Events , Grade 3-4 . If patient discontinue due grade 3 4 adverse event ( i.e . dose-limiting toxicity , DLT ) , additional patient enrol dose level ensure minimum 3 patient evaluate . If 0/3 patient experience dose-limiting ( DLT ) give dose level , dose escalate next cohort 3 patient . If 1/3 patient experience DLT give dose level , additional 3 patient treat dose level . If patient experience DLT , dose escalation continue . If DLT occur 2/3 2/6 patient , dose escalation stop prior dose level declare MTD MSC cell infusion study .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>1 . Patients 4065 year age symptomatic moderate severe ( KellgrenLawrence III IV ) primary osteoarthritis knee 2 . Failed conservative management include physical therapy , brace and/or oral antiinflammatories minimum six month 3 . No history prior intraarticular cortisone , hyaluronic acid , plateletrich plasma injection within previous six month 4 . No history prior arthroscopic knee surgery open knee surgery ipsilateral side within past year 5 . Adequate bone marrow , liver , renal function 6 . Body weight &gt; 40 kg 7 . Body Mass Index &lt; 30 8 . Negative ( HIV , HTLV1 &amp; 2 , Hep A , B , C , syphilis ) infection determine approved serological test 9 . Negative pregnancy determine serum pregnancy test . Females childbearing potential require practice abstinence use effective form contraception 12 month follow MSC injection . 10 . Fluid &gt; 1 cm within lateral recess suprapatellar pouch level superior pole patella knee extend . 1 . Patients clinically unstable knee due presence complete anterior cruciate ligament , posterior cruciate ligament , medial collateral ligament and/or posterolateral corner tear 2 . Patients varus valgus malalignment &gt; 5 degree measure 4 foot stand anteroposterior radiograph 3 . Patients history previous subtotal medial lateral meniscectomy 4 . Patients history septic arthritis affect joint 5 . Patients history prior intraarticular knee fracture 6 . Severe bleed diathesis 7 . Contraindication bone marrow aspiration and/or biopsy 8 . Active infection 9 . Bone marrow failure 10 . Cytopenia 11 . Patients previously receive radiotherapy pelvis 12 . Patients chemotherapy within year date inform 13 . Patients positive serological test ( HIV , HTLV1 &amp; 2 , Hep A , B , C , syphilis ) 14 . Pregnancy risk pregnancy ( include participant willing practice active contraception duration study ) 15 . Patients unforeseen condition deem unsafe inappropriate study ( e.g . patient claustrophobic undergo MRI ) per discretion principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>